Author: BusinessWire

AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan drug designation
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a …

NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Offi…

LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chi…

FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules

Proceeds will enable FogPharma to advance its fir…

FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules

Proceeds will enable FogPharma to advance its fir…

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Phase 3 clinical trial of omidubicel will be present…

Dr. Biller Brings More Than 30 Years of Experience Discovering and Advancing Novel Molecules, Most Recently as Chief Scientific Officer at Agios Pharmaceuticals
CAMBRIDGE, Mass.–(BUSINESS WIRE)–ROME Therapeutics, a biotechnology company harnessing t…

Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD out…

Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD out…